Tags

Type your tag names separated by a space and hit enter

Effects of hemodialysis on plasma oxylipins.
Physiol Rep. 2020 06; 8(12):e14447.PR

Abstract

Chronic kidney disease (CKD) is an important risk factor for cardiovascular and all-cause mortality. Survival rates among end-stage renal disease (ESRD) hemodialysis patients are poor and most deaths are related to cardiovascular disease. Oxylipins constitute a family of oxygenated natural products, formed from fatty acid by pathways involving at least one step of dioxygen-dependent oxidation. They are derived from polyunsaturated fatty acids (PUFAs) by cyclooxygenase (COX) enzymes, by lipoxygenases (LOX) enzymes, or by cytochrome P450 epoxygenase. Oxylipins have physiological significance and some could be of regulatory importance. The effects of decreased renal function and dialysis treatment on oxylipin metabolism are unknown. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments and measured oxylipins (HPLC-MS lipidomics) derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways in circulating blood. We found that all four subclasses of CYP epoxy metabolites were increased after the dialysis treatment. Rather than resulting from altered soluble epoxide hydrolase (sEH) activity, the oxylipins were released and accumulated in the circulation. Furthermore, hemodialysis did not change the majority of LOX/CYP ω/(ω-1)-hydroxylase metabolites. Our data support the idea that oxylipin profiles discriminate ESRD patients from normal controls and are influenced by renal replacement therapies.

Authors+Show Affiliations

Experimental and Clinical Research Center (ECRC), a joint institution between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. HELIOS Klinikum Berlin-Buch, Berlin, Germany.Experimental and Clinical Research Center (ECRC), a joint institution between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.LIPIDOMIX GmbH, Berlin, Germany.LIPIDOMIX GmbH, Berlin, Germany.Experimental and Clinical Research Center (ECRC), a joint institution between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. Department of Geriatrics, University of Greifswald, University District Hospital Wolgast, Greifswald, Germany.Experimental and Clinical Research Center (ECRC), a joint institution between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32562348

Citation

Gollasch, Benjamin, et al. "Effects of Hemodialysis On Plasma Oxylipins." Physiological Reports, vol. 8, no. 12, 2020, pp. e14447.
Gollasch B, Wu G, Dogan I, et al. Effects of hemodialysis on plasma oxylipins. Physiol Rep. 2020;8(12):e14447.
Gollasch, B., Wu, G., Dogan, I., Rothe, M., Gollasch, M., & Luft, F. C. (2020). Effects of hemodialysis on plasma oxylipins. Physiological Reports, 8(12), e14447. https://doi.org/10.14814/phy2.14447
Gollasch B, et al. Effects of Hemodialysis On Plasma Oxylipins. Physiol Rep. 2020;8(12):e14447. PubMed PMID: 32562348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of hemodialysis on plasma oxylipins. AU - Gollasch,Benjamin, AU - Wu,Guanlin, AU - Dogan,Inci, AU - Rothe,Michael, AU - Gollasch,Maik, AU - Luft,Friedrich C, PY - 2020/01/28/received PY - 2020/04/04/revised PY - 2020/04/24/accepted PY - 2020/6/21/entrez PY - 2020/6/21/pubmed PY - 2020/6/21/medline KW - dialysis KW - eicosanoids KW - fatty acids KW - lipidomics KW - oxylipins SP - e14447 EP - e14447 JF - Physiological reports JO - Physiol Rep VL - 8 IS - 12 N2 - Chronic kidney disease (CKD) is an important risk factor for cardiovascular and all-cause mortality. Survival rates among end-stage renal disease (ESRD) hemodialysis patients are poor and most deaths are related to cardiovascular disease. Oxylipins constitute a family of oxygenated natural products, formed from fatty acid by pathways involving at least one step of dioxygen-dependent oxidation. They are derived from polyunsaturated fatty acids (PUFAs) by cyclooxygenase (COX) enzymes, by lipoxygenases (LOX) enzymes, or by cytochrome P450 epoxygenase. Oxylipins have physiological significance and some could be of regulatory importance. The effects of decreased renal function and dialysis treatment on oxylipin metabolism are unknown. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments and measured oxylipins (HPLC-MS lipidomics) derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways in circulating blood. We found that all four subclasses of CYP epoxy metabolites were increased after the dialysis treatment. Rather than resulting from altered soluble epoxide hydrolase (sEH) activity, the oxylipins were released and accumulated in the circulation. Furthermore, hemodialysis did not change the majority of LOX/CYP ω/(ω-1)-hydroxylase metabolites. Our data support the idea that oxylipin profiles discriminate ESRD patients from normal controls and are influenced by renal replacement therapies. SN - 2051-817X UR - https://www.unboundmedicine.com/medline/citation/32562348/Effects_of_hemodialysis_on_plasma_oxylipins_ L2 - https://doi.org/10.14814/phy2.14447 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.